隶属于 shire deutschland gmbh
相关临床试验
387
20 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
20
5.2%
Approved For Marketing
1
0.3%
已完成
309
79.8%
No Longer Available
2
0.5%
招募中
3
0.8%
终止
41
10.6%
撤回
11
2.8%
暂无批准数据
- Modicus Prime raised $8 million in total funding, including a recent $4.5 million round led by Frist Cressey Ventures, to expand its AI compliance infrastructure for pharmaceutical companies. - The company's Trustworthy AI Compliance Software integrates with pharmaceutical technology stacks to provide centralized oversight for AI governance across regulated GxP environments globally. - The platform addresses an industry problem estimated at $50 billion annually in quality control failures by enabling audit-ready AI deployment across pharmaceutical organizations. - CEO Taylor Chartier co-authored the ISPE GAMP AI Guide and has been instrumental in shaping industry standards for AI implementation in regulated pharmaceutical environments.
- Inimmune Corporation has appointed Ferdinand Massari, M.D., as Chief Medical Officer and Ryan McMillian as Head of Financial Strategy to strengthen leadership ahead of Phase 2 INI-2004 allergic rhinitis data readout. - Dr. Massari brings over two decades of clinical development experience in immunology and inflammatory diseases from companies including Shire, Pfizer, Pharmacia, and Merck. - The leadership appointments support Inimmune's strategic expansion of INI-2004 development into allergic asthma and food allergy, conditions affecting millions worldwide. - Mr. McMillian contributes over 20 years of biotech finance experience, including more than $250 million in fundraising for life sciences companies and previous roles at Alexion Pharmaceuticals.
- OKYO Pharma has appointed Robert J. Dempsey as Chief Executive Officer, bringing over two decades of ophthalmology commercialization experience including leadership of blockbuster dry eye therapies Xiidra® and Restasis®. - Dempsey previously led the $3.4 billion upfront sale of Xiidra® to Novartis in 2019, one of only three ophthalmology deals in the past twenty years exceeding $1 billion upfront. - The leadership transition positions OKYO to advance urcosimod, its lead asset for neuropathic corneal pain, a severe ocular condition currently without FDA-approved therapy. - OKYO recently completed a successful Phase 2 trial of urcosimod in neuropathic corneal pain patients and plans to initiate a larger multicenter trial in Q1 2026.
- Sen-Jam Pharmaceutical announced a transformative partnership with TASK Clinical, which will fund two-thirds of the Phase 3 trial for SJP-001 in exchange for equity, representing an exceptionally rare commitment from a global CRO. - SJP-001 is designed as the first FDA-regulated hangover-prevention therapeutic, targeting the inflammatory cascade triggered by alcohol consumption to address symptoms like headache, malaise, nausea, and cognitive impairment. - The company has established a vertically integrated development ecosystem with TASK Clinical providing clinical leadership and majority Phase 3 funding, KVK Tech handling formulation and manufacturing, and Rute Fernandes guiding commercialization strategy. - Phase 2 trial results conducted by Cliantha Research in Toronto are expected in Q1 2026, with the partnership positioning Sen-Jam for accelerated investor engagement and global licensing discussions.
- Abeona Therapeutics has appointed James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. - Dr. Gow brings over 20 years of industry experience in clinical development and medical affairs, with recognized expertise in gene therapy, particularly in ophthalmology. - His clinical development track record includes leading programs from Phase 1 through post-marketing studies that resulted in FDA approvals of multiple drugs including Xibrom, Bromday, Prolensa, and Bepreve. - The appointment strengthens Abeona's leadership as the company advances its pipeline of cell and gene therapies, including ZEVASKYN for recessive dystrophic epidermolysis bullosa and AAV-based gene therapies for ophthalmic diseases.
- Ultragenyx Pharmaceutical appointed Eric Olson as Chief Business Officer and Executive Vice President effective September 22, 2025, following Thomas Kassberg's planned retirement after 14 years with the company. - Olson brings nearly two decades of biopharma business development experience, having led or supported over $15 billion in aggregate transaction value across rare disease and other therapeutic areas. - The appointment positions Ultragenyx to continue expanding what the company describes as the largest clinical pipeline in rare disease, building on four commercial therapies already approved. - Olson's previous roles include Chief Business Officer at Stoke Therapeutics and leadership positions at Alnylam Pharmaceuticals, Takeda, and Genzyme Corporation, with notable deals including partnerships worth billions of dollars.
- DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases. - Recent clinical milestones include Kamada's post-marketing research initiative for CYTOGAM, ACTG's encouraging HIV-CMV study results, and Fortress Biotech's Phase 2 trial initiation for Triplex vaccine. - The CMV pipeline encompasses diverse therapeutic approaches including mRNA vaccines, T-cell therapies, immune globulins, and antiviral compounds from companies like Moderna, Merck Sharp & Dohme, and Chimerix. - Market growth is driven by increasing CMV prevalence and research activities, though high treatment costs and healthcare infrastructure limitations present ongoing challenges.
- Takeda Pharmaceutical is planning significant investments in US operations while reporting minimal anticipated impact from recent tariff policies on their global business strategy. - The Japanese pharmaceutical giant has confirmed three pivotal Phase III clinical trial readouts scheduled for 2025, marking critical milestones in their late-stage pipeline development. - Takeda is preparing two regulatory submissions for 2025, potentially expanding their therapeutic portfolio pending successful trial outcomes and regulatory approval processes.
- Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones. - Dr. Mayer brings extensive experience in clinical development and regulatory affairs, particularly in rare diseases, as Walden prepares for Phase 2 data readout of WAL0921 for glomerular kidney diseases. - The appointment comes at a strategic time as Walden advances its pipeline, including the progression of WAL0623, a dynamin stabilizer, into clinical trials.
- Post-hoc analysis of six phase 3 and 4 clinical trials demonstrates prucalopride's effectiveness in treating chronic idiopathic constipation across different age groups, with significant improvements in bowel movements. - The drug showed strong efficacy in patients with normal to mildly impaired renal function and those with underweight to overweight BMI, though benefits were less pronounced in obese patients. - While more treatment-related adverse events were reported in the prucalopride group, researchers found no unexpected safety concerns across all patient subgroups studied.
